SCHEMBL1237692

SCHEMBL1237692

CCOC(=O)OB(O)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.44
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 3/20 0.41
PIN1 Q13526 2/20 0.41
GAA P10253 1/20 0.41
NPC1 O15118 1/20 0.40
MAPT P10636 1/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HSD11B1 P28845 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6829989 0.84 TSHR (0.46) TSHRMEN1KMT2AALDH1A1PIN1
SCHEMBL2359233 0.83 TSHR (0.50) TSHRMEN1KMT2AALDH1A1LMNA
SCHEMBL1237722 0.81 ALDH1A1 (0.53) MEN1KMT2AALDH1A1LMNAHSD17B10
SCHEMBL28664851 0.81 TRPV6 (0.44) TSHRALDH1A1LMNAL3MBTL1
SCHEMBL1237453 0.79 KMT2A (0.42) TSHRKMT2AALDH1A1MAPTHSD17B10
Hydrochloric Acid SCHEMBL3987325 0.78 KMT2A (0.41) TSHRKMT2AALDH1A1MAPTHSD17B10
SCHEMBL4508305 0.78 ELANE (0.42) TSHRALDH1A1GAAMAPTLMNA
SCHEMBL6931923 0.76 NPC1 (0.42) TSHRMEN1KMT2AALDH1A1PIN1
SCHEMBL18424371 0.75 CYP2C19 (0.39) TSHRMEN1KMT2AALDH1A1GAA
SCHEMBL651370 0.75 ORAI1 (0.42) TSHRALDH1A1GAAMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115433364-A Hydrogen bond organic molecular framework material HOF-NBDA and preparation method and application thereof 中国科学院福建物质结构研究所 2022-12-06 CN claimed
US-9162999-B2 Catalytic conversion of cellulose to fuels and chemicals using boronic acids WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2015-10-20 US claimed
EP-2059227-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY Aeris Therapeutics, Inc. (US) 2009-05-20 EP claimed
WO-2008039827-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY AERIS THERAPEUTICS, INC. (US) 2008-04-03 WO claimed
CN-115433364-B Hydrogen bond organic molecular framework material HOF-NBDA, and preparation method and application thereof 中国科学院福建物质结构研究所 2023-09-08 CN disclosed
US-20230181462-A1 Dynamic Covalent Hydrogels, Precursors Thereof and Uses Thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2023-06-15 US disclosed
EP-4118136-A1 DYNAMIC COVALENT HYDROGELS, PRECURSORS THEREOF AND USES THEREOF Centre National de la Recherche Scientifique (CNRS) (FR) 2023-01-18 EP disclosed
CN-115433364-A Hydrogen bond organic molecular framework material HOF-NBDA and preparation method and application thereof 中国科学院福建物质结构研究所 2022-12-06 CN disclosed
CN-114262340-A Preparation method of aminophenylboronic acid 蚌埠中实化学技术有限公司 2022-04-01 CN disclosed
EP-3790883-A1 HETEROARYL COMPOUNDS AND USES THEREOF Aprinoia Therapeutics Inc. (TW) 2021-03-17 EP disclosed
WO-2019214681-A1 HETEROARYL COMPOUNDS AND USES THEREOF APRINOIA THERAPEUTICS INC. (CN) 2019-11-14 WO disclosed
US-10032986-B2 Polycyclic compound and organic light emitting device including the same LG CHEM, LTD. (KR) 2018-07-24 US disclosed
US-20070287705-A1 Crf Receptor Antagonists and Methods Relating Thereto NEUROCRINE BIOSCIENCES, INC. 2007-12-13 US disclosed
WO-2007130468-A2 PYRIDO [2, 3-B] PYRAZINE AND [1, 8] -NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS CEPHALON, INC. (US) 2007-11-15 WO disclosed
EP-1815206-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC Therapeutics, Inc. (US) 2007-08-08 EP disclosed
WO-2007070045-A1 PREPARATION OF SUBSTITUTED BRIDGED INDENYL AND RELATED LIGANDS EXXONMOBIL CHEMICAL PATENTS, INC. (US) 2007-06-21 WO disclosed
EP-1697374-A1 CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO SB Pharmco Puerto Rico Inc. (PR) 2006-09-06 EP disclosed
WO-2006044456-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC THERAPEUTICS, INC. (US) 2006-04-27 WO disclosed
WO-2005063755-A1 CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO SB PHARMCO PUERTO RICO INC (US) 2005-07-14 WO disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287705-A1 Crf Receptor Antagonists and Methods Relating Thereto CRHR1, CRHR2, CRH TSHR 220/4885MEN1 1737/4885KMT2A 3165/4885
US-10032986-B2 Polycyclic compound and organic light emitting device including the same PPOX, CRY1, CRY2 TSHR 4236/4885MEN1 643/4885KMT2A 170/4885
US-20230181462-A1 Dynamic Covalent Hydrogels, Precursors Thereof and Uses Thereof CDC37, ILK, PTMS TSHR 4380/4885MEN1 4666/4885KMT2A 2860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.